Compare PW & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PW | NXTS |
|---|---|---|
| Founded | 1967 | 2009 |
| Country | United States | Israel |
| Employees | 2 | 9 |
| Industry | Real Estate Investment Trusts | Agricultural Chemicals |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.3M |
| IPO Year | N/A | N/A |
| Metric | PW | NXTS |
|---|---|---|
| Price | $0.60 | $4.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 43.1K | 19.6K |
| Earning Date | 05-13-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.55 |
| 52 Week High | $1.96 | $6.21 |
| Indicator | PW | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 32.95 | 53.90 |
| Support Level | N/A | $3.92 |
| Resistance Level | $0.91 | $5.31 |
| Average True Range (ATR) | 0.06 | 0.62 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 21.03 | 23.16 |
Power REIT is an internally-managed real estate investment trust that owns a portfolio of real estate assets related to transportation, energy infrastructure and Controlled Environment Agriculture in the United States. Its assets consisted of approximately 112 miles of railroad infrastructure and related real estate which is owned by its subsidiary, approximately 447 acres of fee simple land leased to a utility scale solar power generating project with an aggregate generating capacity of approximately 82 Megawatts and approximately 82 acres of land with approximately 357,000 square feet of CEA properties in the form of greenhouses. The company invested in greenhouses for state-licensed cannabis and food cultivation.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.